Previous close | 1.0400 |
Open | 0.9800 |
Bid | 0.9745 x 100 |
Ask | 1.0500 x 100 |
Day's range | 0.9800 - 1.0200 |
52-week range | 0.7400 - 11.9100 |
Volume | |
Avg. volume | 53,331 |
Market cap | 6.619M |
Beta (5Y monthly) | -0.04 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.2800 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 25.00 |
ATLANTA, December 11, 2023--Alzamend Neuro Receives FDA "Study May Proceed" Notice for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug to Treat PTSD
ATLANTA, November 20, 2023--Alzamend Gets FDA "Study May Proceed" Notice for Phase IIA Clinical Trial of AL001 a Next-Generation Lithium Therapeutic for Major Depressive Disorder
ATLANTA, November 16, 2023--Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement